Cited 38 times in
Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경식 | - |
dc.contributor.author | 김윤재 | - |
dc.contributor.author | 박병규 | - |
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 이우정 | - |
dc.contributor.author | 정재복 | - |
dc.contributor.author | 최진섭 | - |
dc.date.accessioned | 2015-06-10T12:28:14Z | - |
dc.date.available | 2015-06-10T12:28:14Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109860 | - |
dc.description.abstract | BACKGROUND: The aim of this phase II study was to determine the efficacy of gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer. METHODS: Eligibility criteria included histologically confirmed adenocarcinoma with measurable tumor in the biliary tract that was unresectable and either locally advanced or metastatic. Patients received a combination of gemcitabine (1000 mg/m(2) intravenously [IV] on days 1, 8, and 15) and cisplatin (75 mg/m(2) IV on day 1). Cycles were repeated every 28 days. Objective tumor response rates and toxicities were evaluated according to World Health Organization criteria. RESULTS: Twenty-seven patients were enrolled in the study and a total of 120 cycles of chemotherapy were administrated. Objective partial response was observed in nine (33.3%) patients, while stable disease was found in seven (25.9%) patients. The median survival time was 10.0 months and the 1-year survival rate was 36%. Median time to disease progression was 5.6 months. The most common grade 3-4 toxicities were leukopenia (25.9%), anemia (29.6%), thrombocytopenia (22.2%), and vomiting (18.5%). Only one patient was hospitalized for chemotherapy-related complications. CONCLUSION: Gemcitabine and cisplatin combination chemotherapy is an effective, safe, and well-tolerated regimen for the treatment of advanced biliary tract cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 999~1003 | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols* | - |
dc.subject.MESH | Biliary Tract Neoplasms/drug therapy* | - |
dc.subject.MESH | Cisplatin/administration & dosage* | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Byung Kyu Park | - |
dc.contributor.googleauthor | Yoon Jae Kim | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.contributor.googleauthor | Jae Bock Chung | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Jin-Sub Choi | - |
dc.contributor.googleauthor | Woo Jung Lee | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.identifier.doi | 10.1111/j.1440-1746.2006.04230.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00299 | - |
dc.contributor.localId | A00792 | - |
dc.contributor.localId | A01473 | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A03706 | - |
dc.contributor.localId | A04199 | - |
dc.contributor.localId | A02993 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 16724985 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2006.04230.x/abstract | - |
dc.subject.keyword | biliary tract cancer | - |
dc.subject.keyword | chemotherapy | - |
dc.subject.keyword | cisplatin | - |
dc.subject.keyword | gemcitabine | - |
dc.contributor.alternativeName | Kim, Kyung Sik | - |
dc.contributor.alternativeName | Kim, Yoon Jae | - |
dc.contributor.alternativeName | Park, Byung Kyu | - |
dc.contributor.alternativeName | Park, Seung Woo | - |
dc.contributor.alternativeName | Park, Jeong Youp | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Lee, Woo Jung | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.alternativeName | Choi, Jin Sub | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Sik | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.contributor.affiliatedAuthor | Park, Byung Kyu | - |
dc.contributor.affiliatedAuthor | Park, Seung Woo | - |
dc.contributor.affiliatedAuthor | Park, Jeong Youp | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | Choi, Jin Sub | - |
dc.contributor.affiliatedAuthor | Lee, Woo Jung | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 21 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 999 | - |
dc.citation.endPage | 1003 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.21(6) : 999-1003, 2006 | - |
dc.identifier.rimsid | 50643 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.